Insulet Corp. (PODD) EV/FCF Ratio: 26.49x
Is Insulet Corp.’s EV/FCF ratio high or low?
Insulet Corp.'s EV/FCF ratio of 26.49x is 66% below its 2-year average of 77.25x, near the low end of its 2-year range (24.80x–207.85x).
As of Thursday, June 25, 2026. 48.05% below its 12-month average of 50.99x.
PODD EV/FCF Ratio Chart
PODD Average EV/FCF Ratio Chart
PODD Current vs Average EV/FCF Ratio Chart
PODD EV/FCF Ratio Metrics
EV/FCF RATIO
26.49x
EV/FCF RATIO AVG TTM
50.99x
EV/FCF RATIO AVG 3Y
66.66x
EV/FCF RATIO AVG 5Y
66.66x
EV/FCF RATIO AVG 10Y
66.66x
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-48.05%
CURRENT VS 3Y AVG
-60.26%
CURRENT VS 5Y AVG
-60.26%
CURRENT VS 10Y AVG
-60.26%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
PODD Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $10.31B | 26.49x | 50.99x | 66.66x | 66.66x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 66.60x | 67.40x | 78.57x | 42.55x |
| Baxter International Inc. (BAX)vs › | $10.38B | 25.24x | 65.14x | 51.47x | 47.28x |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.73B | 32.60x | 21.68x | 28.86x | 35.14x |
| Revvity, Inc. (RVTY)vs › | $11.14B | 27.67x | 26.80x | 265.77x | 164.25x |
| Henry Schein, Inc. (HSIC)vs › | $9.38B | 29.95x | 28.78x | 26.64x | 23.96x |
| Align Technology, Inc. (ALGN)vs › | $12.24B | 16.46x | 17.62x | 29.16x | 38.60x |
| Oscar Health, Inc. (OSCR)vs › | $7.76B | 1.96x | 2.34x | 4.12x | 4.38x |
| Solventum Corporation (SOLV)vs › | $13.01B | N/A | 157.09x | 88.54x | 88.54x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.57B | 23.57x | 25.15x | 42.61x | 51.04x |
Cash Flow Valuation Comparison
EV/FCF
26.5x
P/FCF
25.4x
FCF Yield
3.94%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Insulet Corp. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Insulet Corp. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Insulet Corp. (PODD)?
- The EV/FCF ratio for PODD stock is 26.49x.
- Is Insulet Corp.'s EV/FCF ratio high or low?
- Insulet Corp.'s EV/FCF ratio of 26.49x is 66% below its 2-year average of 77.25x, near the low end of its 2-year range (24.80x–207.85x).
- What is the TTM average EV/FCF ratio for Insulet Corp. (PODD)?
- The TTM average EV/FCF ratio for PODD stock is 50.99x.
- What is the 3Y average EV/FCF ratio for Insulet Corp. (PODD)?
- The 3Y average EV/FCF ratio for PODD stock is 66.66x.
- What is the 5Y average EV/FCF ratio for Insulet Corp. (PODD)?
- The 5Y average EV/FCF ratio for PODD stock is 66.66x.
- What is the 10Y average EV/FCF ratio for Insulet Corp. (PODD)?
- The 10Y average EV/FCF ratio for PODD stock is 66.66x.
Insulet Corp. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-24 | 26.49x |
| 2026-06-23 | 25.64x |
| 2026-06-22 | 24.80x |
| 2026-06-18 | 25.96x |
| 2026-06-17 | 25.58x |
| 2026-06-16 | 26.29x |
| 2026-06-15 | 26.36x |
| 2026-06-12 | 26.63x |
| 2026-06-11 | 26.54x |
| 2026-06-10 | 26.80x |
| 2026-06-09 | 28.32x |
| 2026-06-08 | 26.94x |
| 2026-06-05 | 27.23x |
| 2026-06-04 | 26.07x |
| 2026-06-03 | 25.54x |
| 2026-06-02 | 25.39x |
| 2026-06-01 | 26.36x |
| 2026-05-29 | 25.82x |
| 2026-05-28 | 25.43x |
| 2026-05-27 | 26.00x |
| 2026-05-26 | 27.33x |
| 2026-05-22 | 27.51x |
| 2026-05-21 | 27.85x |
| 2026-05-20 | 27.80x |
| 2026-05-19 | 27.47x |
| 2026-05-18 | 27.11x |
| 2026-05-15 | 26.25x |
| 2026-05-14 | 26.46x |
| 2026-05-13 | 26.48x |
| 2026-05-12 | 28.10x |
| 2026-05-11 | 27.39x |
| 2026-05-08 | 27.39x |
| 2026-05-07 | 28.45x |
| 2026-05-06 | 26.90x |
| 2026-05-05 | 32.23x |
| 2026-05-04 | 32.95x |
| 2026-05-01 | 33.64x |
| 2026-04-30 | 33.09x |
| 2026-04-29 | 30.83x |
| 2026-04-28 | 35.10x |
| 2026-04-27 | 36.12x |
| 2026-04-24 | 36.35x |
| 2026-04-23 | 36.85x |
| 2026-04-22 | 37.11x |
| 2026-04-21 | 36.87x |
| 2026-04-20 | 38.47x |
| 2026-04-17 | 39.00x |
| 2026-04-16 | 38.58x |
| 2026-04-15 | 38.77x |
| 2026-04-14 | 38.58x |
| 2026-04-13 | 37.90x |
| 2026-04-10 | 37.73x |
| 2026-04-09 | 38.20x |
| 2026-04-08 | 38.96x |
| 2026-04-07 | 38.77x |
| 2026-04-06 | 38.96x |
| 2026-04-02 | 39.11x |
| 2026-04-01 | 39.62x |
| 2026-03-31 | 40.15x |
| 2026-03-30 | 39.80x |
| 2026-03-27 | 39.84x |
| 2026-03-26 | 41.69x |
| 2026-03-25 | 41.30x |
| 2026-03-24 | 43.08x |
| 2026-03-23 | 43.37x |
| 2026-03-20 | 43.38x |
| 2026-03-19 | 43.66x |
| 2026-03-18 | 43.97x |
| 2026-03-17 | 44.01x |
| 2026-03-16 | 42.92x |
| 2026-03-13 | 42.02x |
| 2026-03-12 | 45.05x |
| 2026-03-11 | 45.57x |
| 2026-03-10 | 45.46x |
| 2026-03-09 | 45.86x |
| 2026-03-06 | 45.23x |
| 2026-03-05 | 45.97x |
| 2026-03-04 | 46.33x |
| 2026-03-03 | 46.13x |
| 2026-03-02 | 46.81x |
| 2026-02-27 | 47.03x |
| 2026-02-26 | 47.94x |
| 2026-02-25 | 47.31x |
| 2026-02-24 | 46.77x |
| 2026-02-23 | 47.54x |
| 2026-02-20 | 46.14x |
| 2026-02-19 | 47.49x |
| 2026-02-18 | 49.17x |
| 2026-02-17 | 41.98x |
| 2026-02-13 | 41.37x |
| 2026-02-12 | 41.05x |
| 2026-02-11 | 42.73x |
| 2026-02-10 | 42.99x |
| 2026-02-09 | 41.85x |
| 2026-02-06 | 41.24x |
| 2026-02-05 | 41.44x |
| 2026-02-04 | 42.80x |
| 2026-02-03 | 42.80x |
| 2026-02-02 | 43.70x |
| 2026-01-30 | 43.57x |
| 2026-01-29 | 43.45x |
| 2026-01-28 | 43.97x |
| 2026-01-27 | 45.09x |
| 2026-01-26 | 46.17x |
| 2026-01-23 | 46.21x |
| 2026-01-22 | 47.62x |
| 2026-01-21 | 48.46x |
| 2026-01-20 | 48.34x |
| 2026-01-16 | 48.92x |
| 2026-01-15 | 48.71x |
| 2026-01-14 | 48.11x |
| 2026-01-13 | 47.32x |
| 2026-01-12 | 47.38x |
| 2026-01-09 | 49.14x |
| 2026-01-08 | 49.79x |
| 2026-01-07 | 50.84x |
| 2026-01-06 | 50.03x |
| 2026-01-05 | 48.21x |
| 2026-01-02 | 48.11x |
| 2025-12-31 | 48.33x |
| 2025-12-30 | 48.80x |
| 2025-12-29 | 48.86x |
| 2025-12-26 | 49.07x |
| 2025-12-24 | 49.10x |
| 2025-12-23 | 48.55x |
| 2025-12-22 | 49.56x |
| 2025-12-19 | 49.24x |
| 2025-12-18 | 49.78x |
| 2025-12-17 | 49.23x |
| 2025-12-16 | 49.09x |
| 2025-12-15 | 49.55x |
| 2025-12-12 | 50.26x |
| 2025-12-11 | 50.00x |
| 2025-12-10 | 50.17x |
| 2025-12-09 | 50.01x |
| 2025-12-08 | 50.34x |
| 2025-12-05 | 51.73x |
| 2025-12-04 | 53.65x |
| 2025-12-03 | 52.25x |
| 2025-12-02 | 52.49x |
| 2025-12-01 | 52.80x |
| 2025-11-28 | 55.54x |
| 2025-11-26 | 55.47x |
| 2025-11-25 | 55.82x |
| 2025-11-24 | 57.27x |
| 2025-11-21 | 56.21x |
| 2025-11-20 | 53.14x |
| 2025-11-19 | 58.76x |
| 2025-11-18 | 56.59x |
| 2025-11-17 | 55.68x |
| 2025-11-14 | 56.46x |
| 2025-11-13 | 56.46x |
| 2025-11-12 | 57.16x |
| 2025-11-11 | 55.39x |
| 2025-11-10 | 54.39x |
| 2025-11-07 | 54.30x |
| 2025-11-06 | 54.90x |
| 2025-11-05 | 58.30x |
| 2025-11-04 | 59.36x |
| 2025-11-03 | 59.09x |
| 2025-10-31 | 58.04x |
| 2025-10-30 | 57.84x |
| 2025-10-29 | 58.61x |
| 2025-10-28 | 60.10x |
| 2025-10-27 | 60.36x |
| 2025-10-24 | 59.47x |
| 2025-10-23 | 59.94x |
| 2025-10-22 | 60.99x |
| 2025-10-21 | 60.94x |
| 2025-10-20 | 60.56x |
| 2025-10-17 | 59.05x |
| 2025-10-16 | 58.63x |
| 2025-10-15 | 57.94x |
| 2025-10-14 | 59.00x |
| 2025-10-13 | 58.32x |
| 2025-10-10 | 58.31x |
| 2025-10-09 | 59.38x |
| 2025-10-08 | 58.49x |
| 2025-10-07 | 58.12x |
| 2025-10-06 | 57.80x |
| 2025-10-03 | 57.33x |
| 2025-10-02 | 57.89x |
| 2025-10-01 | 56.76x |
| 2025-09-30 | 57.26x |
| 2025-09-29 | 57.60x |
| 2025-09-26 | 58.94x |
| 2025-09-25 | 59.96x |
| 2025-09-24 | 60.58x |
| 2025-09-23 | 60.73x |
| 2025-09-22 | 62.06x |
| 2025-09-19 | 61.28x |
| 2025-09-18 | 61.77x |
| 2025-09-17 | 59.71x |
| 2025-09-16 | 61.52x |
| 2025-09-15 | 63.00x |
| 2025-09-12 | 63.27x |
| 2025-09-11 | 62.57x |
| 2025-09-10 | 62.51x |
| 2025-09-09 | 65.28x |
| 2025-09-08 | 64.69x |
| 2025-09-05 | 64.48x |
| 2025-09-04 | 64.12x |
| 2025-09-03 | 63.59x |
| 2025-09-02 | 63.84x |
| 2025-08-29 | 62.93x |
| 2025-08-28 | 62.51x |
| 2025-08-27 | 61.92x |
| 2025-08-26 | 61.46x |
| 2025-08-25 | 60.95x |
| 2025-08-22 | 61.27x |
| 2025-08-21 | 60.74x |
| 2025-08-20 | 61.67x |
| 2025-08-19 | 60.67x |
| 2025-08-18 | 59.87x |
| 2025-08-15 | 59.54x |
| 2025-08-14 | 58.54x |
| 2025-08-13 | 57.25x |
| 2025-08-12 | 57.42x |
| 2025-08-11 | 56.55x |
| 2025-08-08 | 56.96x |
| 2025-08-07 | 56.32x |
| 2025-08-06 | 75.06x |
| 2025-08-05 | 76.04x |
| 2025-08-04 | 77.83x |
| 2025-08-01 | 77.08x |
| 2025-07-31 | 78.00x |
| 2025-07-30 | 80.62x |
| 2025-07-29 | 78.82x |
| 2025-07-28 | 79.03x |
| 2025-07-25 | 78.48x |
| 2025-07-24 | 77.52x |
| 2025-07-23 | 77.54x |
| 2025-07-22 | 77.25x |
| 2025-07-21 | 76.03x |
| 2025-07-18 | 76.90x |
| 2025-07-17 | 76.69x |
| 2025-07-16 | 77.97x |
| 2025-07-15 | 78.42x |
| 2025-07-14 | 78.96x |
| 2025-07-11 | 78.25x |
| 2025-07-10 | 80.39x |
| 2025-07-09 | 80.41x |
| 2025-07-08 | 80.15x |
| 2025-07-07 | 81.27x |
| 2025-07-03 | 81.36x |
| 2025-07-02 | 81.51x |
| 2025-07-01 | 81.08x |
| 2025-06-30 | 84.84x |
| 2025-06-27 | 84.55x |
| 2025-06-26 | 83.69x |
| 2025-06-25 | 82.73x |
| 2025-06-24 | 83.97x |
| 2025-06-23 | 83.12x |
| 2025-06-20 | 81.92x |
| 2025-06-18 | 81.55x |
| 2025-06-17 | 82.24x |
| 2025-06-16 | 82.83x |
| 2025-06-13 | 82.31x |
| 2025-06-12 | 82.04x |
| 2025-06-11 | 81.67x |
Showing the most recent 260 of 662 data points. The chart above shows the full history.
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy